- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Senate passes Drug Quality and Security Act
- Rite Aid posts third consecutive quarterly profit as company expands Wellness+
WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has started shipping two formulations of a generic drug for treating migraines, the company said.
Par announced the shipment of rizatriptan benzoate tablets and rizatriptan benzoate orally disintegrating tablets in the 5-mg and 10-mg strengths. The drug is used to treat acute migraine with or without aura in patients ages 6 years and older.
The drug has sales of about $653 million per year, according to IMS Health.